In the case of ATTR cardiomyopathy, Acoramidis exhibits encouraging outcomes.

Published Date: 29 Aug 2023

It was "robustly positive," according to the ATTRibute-CM trial's lead author, and it suggests "the tantalizing possibility of genuine clinical improvements" for this fatal and progressive condition.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?

2.

Health of Myeloma Patient's Marriage Tied to Recovery After Transplant

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

5.

From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot